Jiangsu Bioperfectus Technologies Co., Ltd.
SSE:688399.SS
74.43 (CNY) • At close June 6, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 349.609 | 403.179 | 5,534.793 | 2,839.036 | 1,739.681 | 288.795 | 230.7 | 187.286 | 129.142 |
| Cost of Revenue
| 131.954 | 253.938 | 2,179.835 | 876.346 | 389.86 | 52.685 | 42.282 | 32.451 | 23.661 |
| Gross Profit
| 217.655 | 149.241 | 3,354.958 | 1,962.69 | 1,349.821 | 236.11 | 188.419 | 154.835 | 105.481 |
| Gross Profit Ratio
| 0.623 | 0.37 | 0.606 | 0.691 | 0.776 | 0.818 | 0.817 | 0.827 | 0.817 |
| Reseach & Development Expenses
| 100.887 | 136.176 | 185.823 | 106.638 | 72.066 | 38.558 | 26.384 | 21.411 | 14.313 |
| General & Administrative Expenses
| 25.595 | 89.991 | 124.706 | 46.092 | 43.435 | 8.321 | 8.097 | 19.298 | 36.003 |
| Selling & Marketing Expenses
| 46.591 | 200.233 | 422.547 | 416.732 | 297.438 | 88.233 | 79.482 | 73.189 | 49.095 |
| SG&A
| 72.186 | 406.998 | 547.253 | 462.824 | 340.873 | 96.555 | 87.579 | 92.487 | 85.097 |
| Other Expenses
| 35.767 | -28.876 | 161.501 | 35.329 | -2.266 | 10.008 | -0.319 | 0.171 | 5.189 |
| Operating Expenses
| 208.84 | 514.298 | 894.577 | 604.791 | 410.673 | 145.121 | 123.202 | 109.576 | 99.926 |
| Operating Income
| 8.815 | -382.779 | 2,149.695 | 1,394.907 | 963.007 | 95.041 | 73.291 | 50.56 | 8.36 |
| Operating Income Ratio
| 0.025 | -0.949 | 0.388 | 0.491 | 0.554 | 0.329 | 0.318 | 0.27 | 0.065 |
| Total Other Income Expenses Net
| -4.627 | 7.109 | -10.986 | -3.132 | -2.017 | -0.34 | -0.319 | 0.171 | 5.189 |
| Income Before Tax
| 4.187 | -375.67 | 2,138.709 | 1,391.776 | 960.99 | 94.701 | 72.972 | 50.731 | 13.549 |
| Income Before Tax Ratio
| 0.012 | -0.932 | 0.386 | 0.49 | 0.552 | 0.328 | 0.316 | 0.271 | 0.105 |
| Income Tax Expense
| 6.189 | -1.859 | 310.808 | 198.561 | 141.423 | 10.945 | 9.147 | 8.062 | 5.188 |
| Net Income
| -2.002 | -373.811 | 1,827.9 | 1,193.214 | 819.567 | 83.756 | 63.825 | 42.668 | 8.361 |
| Net Income Ratio
| -0.006 | -0.927 | 0.33 | 0.42 | 0.471 | 0.29 | 0.277 | 0.228 | 0.065 |
| EPS
| -0.035 | -6.38 | 31.18 | 20.36 | 13.98 | 1.43 | 1.45 | 0.97 | 0.21 |
| EPS Diluted
| -0.035 | -6.38 | 31.18 | 20.36 | 13.98 | 1.43 | 1.45 | 0.97 | 0.21 |
| EBITDA
| 70.63 | -255.063 | 2,251.991 | 1,450.668 | 933.051 | 108.352 | 79.089 | 62.747 | 22.107 |
| EBITDA Ratio
| 0.202 | -0.633 | 0.407 | 0.511 | 0.536 | 0.375 | 0.343 | 0.335 | 0.171 |